Understanding how colorectal cancer develops resistance to targeted therapies
Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response
This study is looking at how colorectal cancer can become resistant to certain treatments by examining changes in the cancer's genes, with the goal of finding new ways to make treatments work better for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11111920 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind how colorectal cancer (CRC) becomes resistant to targeted therapies, particularly focusing on genetic changes that occur in tumors. By analyzing chromosomal instability and gene amplifications, the study aims to identify vulnerabilities in cancer cells that could be targeted to improve treatment outcomes. Patients will be monitored for specific genetic markers that may indicate how their cancer is responding to therapy, potentially leading to more personalized treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who are undergoing targeted therapy.
Not a fit: Patients with early-stage colorectal cancer or those not receiving targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to longer-lasting responses to targeted therapies for colorectal cancer patients.
How similar studies have performed: Previous research has shown that targeting genetic vulnerabilities in cancer cells can lead to improved treatment outcomes, suggesting that this approach may be promising.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Yaeger, Rona — Sloan-Kettering Inst Can Research
- Study coordinator: Yaeger, Rona
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.